146 related articles for article (PubMed ID: 21273938)
1. Immunogenicity of trivalent influenza vaccine in extremely low-birth-weight, premature versus term infants.
D'Angio CT; Heyne RJ; Duara S; Holmes LC; O'Shea TM; Wang H; Wang D; Sánchez PJ; Welliver RC; Ryan RM; Schnabel KC; Hall CB;
Pediatr Infect Dis J; 2011 Jul; 30(7):570-4. PubMed ID: 21273938
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
Rodriguez Weber MA; Claeys C; Aranza Doniz C; Feng Y; Innis BL; Jain VK; Peeters M
Pediatr Infect Dis J; 2014 Dec; 33(12):1262-9. PubMed ID: 25386965
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
Englund JA; Walter E; Black S; Blatter M; Nyberg J; Ruben FL; Decker MD;
Pediatr Infect Dis J; 2010 Feb; 29(2):105-10. PubMed ID: 19934787
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants.
Halasa NB; Gerber MA; Chen Q; Wright PF; Edwards KM
J Infect Dis; 2008 May; 197(10):1448-54. PubMed ID: 18444800
[TBL] [Abstract][Full Text] [Related]
5. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
6. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial to compare the safety and immunogenicity of CSL Limited's 2009 trivalent inactivated influenza vaccine to an established vaccine in United States children.
Brady RC; Hu W; Houchin VG; Eder FS; Jackson KC; Hartel GF; Sawlwin DC; Albano FR; Greenberg M
Vaccine; 2014 Dec; 32(52):7141-7. PubMed ID: 25454878
[TBL] [Abstract][Full Text] [Related]
8. Safety of high dose trivalent inactivated influenza vaccine in pediatric patients with acute lymphoblastic leukemia.
McManus M; Frangoul H; McCullers JA; Wang L; O'Shea A; Halasa N
Pediatr Blood Cancer; 2014 May; 61(5):815-20. PubMed ID: 24249544
[TBL] [Abstract][Full Text] [Related]
9. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of Hemagglutination-Inhibiting Antibodies Following Maternal Influenza Vaccination Among Mothers With and Those Without HIV Infection and Their Infants.
Nunes MC; Cutland CL; Dighero B; Bate J; Jones S; Hugo A; van Niekerk N; Kuwanda L; Izu A; Weinberg A; Madhi SA;
J Infect Dis; 2015 Dec; 212(12):1976-87. PubMed ID: 26080370
[TBL] [Abstract][Full Text] [Related]
11. Influenza Β/Victoria antigen induces strong recall of Β/Yamagata but lower Β/Victoria response in children primed with two doses of Β/Yamagata.
Skowronski DM; Hottes TS; De Serres G; Ward BJ; Janjua NZ; Sabaiduc S; Chan T; Petric M
Pediatr Infect Dis J; 2011 Oct; 30(10):833-9. PubMed ID: 21857263
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis.
Ruiz-Palacios GM; Leroux-Roels G; Beran J; Devaster JM; Esen M; Launay O; McElhaney JE; van Essen GA; Benoit A; Claeys C; Dewé W; Durand C; Duval X; Falsey AR; Feldman G; Galtier F; Gervais P; Hwang SJ; McNeil S; Richardus JH; Trofa A; Oostvogels L;
Hum Vaccin Immunother; 2016 Dec; 12(12):3043-3055. PubMed ID: 27690762
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.
Langley JM; Scheifele DW; Quach C; Vanderkooi OG; Ward B; McNeil S; Dobson S; Kellner JD; Kuhn S; Kollman T; MacKinnon-Cameron D; Smith B; Li Y; Halperin SA
Vaccine; 2012 May; 30(23):3389-94. PubMed ID: 22469860
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
Neuzil KM; Jackson LA; Nelson J; Klimov A; Cox N; Bridges CB; Dunn J; DeStefano F; Shay D
J Infect Dis; 2006 Oct; 194(8):1032-9. PubMed ID: 16991077
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
Greenberg DP; Robertson CA; Noss MJ; Blatter MM; Biedenbender R; Decker MD
Vaccine; 2013 Jan; 31(5):770-6. PubMed ID: 23228813
[TBL] [Abstract][Full Text] [Related]
17. Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age.
Halasa NB; Gerber MA; Berry AA; Anderson EL; Winokur P; Keyserling H; Eckard AR; Hill H; Wolff MC; McNeal MM; Edwards KM; Bernstein DI
J Pediatric Infect Dis Soc; 2015 Sep; 4(3):214-24. PubMed ID: 26334249
[TBL] [Abstract][Full Text] [Related]
18. Trivalent inactivated influenza virus vaccine given to two-month-old children: an off-season pilot study.
Walter EB; Englund JA; Blatter M; Nyberg J; Ruben FL; Decker MD;
Pediatr Infect Dis J; 2009 Dec; 28(12):1099-104. PubMed ID: 19935270
[TBL] [Abstract][Full Text] [Related]
19. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children.
Hoft DF; Babusis E; Worku S; Spencer CT; Lottenbach K; Truscott SM; Abate G; Sakala IG; Edwards KM; Creech CB; Gerber MA; Bernstein DI; Newman F; Graham I; Anderson EL; Belshe RB
J Infect Dis; 2011 Sep; 204(6):845-53. PubMed ID: 21846636
[TBL] [Abstract][Full Text] [Related]
20. Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children.
Nolan T; Bravo L; Ceballos A; Mitha E; Gray G; Quiambao B; Patel SS; Bizjajeva S; Bock H; Nazaire-Bermal N; Forleo-Neto E; Cioppa GD; Narasimhan V
Vaccine; 2014 Oct; 32(46):6146-56. PubMed ID: 25223266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
